One of the strengths of this study is that it is the first comprehensive meta-analysis to include VEGFR-TKIs, IO, and IO+TKI combinations, providing a broader understanding of neoadjuvant therapy in high-complexity RCC. The gene discussed is KDR; the disease is renal cell carcinoma.